Development of the emulsion composition and technology based on iron oleate micelles

This paper addresses the problem of drugs for the treatment of iron deficiency anemia (IDA). Iron deficiency anemia is a clinical and hematological syndrome based on a violation of hemoglobin synthesis resulting from iron deficiency. Clinically, IDA is manifested by symptoms of anemia and sideropenia. The aim of the study is to develop new drugs for the treatment of IDA based on lipophilic iron compounds with oleic acid in the form of a microemulsion. Analogues of the developed compounds are presented on the pharmaceutical market, being registered exclusively as biologically active food additives (Lipofer, Sideral Forte). During the study, the following materials and methods were used: iron (III) oleate with an iron ion concentration of 25 mg/g was obtained by mixing 1.1 g (0.03 mol) of iron nitrate with 6.0 g (0.21 mol) of oleic acids. After that, the mixture was heated to 90℃ for 24 hours under constant stirring. To 3 g of the previously obtained iron (III) oleate solution, 0.56 g of ascorbyl palmitate was added in an equimolar ratio to the iron ion. The mixture was stirred for 24 hours at 90℃. The resulting iron (II) oleate emulsion showed the presence of divalent ions at a concentration of 4.77 mg/g. The total concentration of iron ions in the analyzed oleates of both types was the same. Recalculation for the initial solution in oleic acid showed that the concentration was close to the expected values. Solutions for quantifying the concentrations of the active substances of the drugs under development have been presented. The fundamental possibility of carrying out the in situ reduction of the iron ion in oleic acid using a lipophilic reducing agent, ascorbyl palmitate, has been demonstrated.